Principles for consistent value assessment and sustainable funding of orphan drugs in Europe-Reference-Cited by-同舟云学术

Principles for consistent value assessment and sustainable funding of orphan drugs in Europe

Published:2015-05-03 Issue:1 Volume:10 Page:
ISSN:1750-1172
Container-title:Orphanet Journal of Rare Diseases
language:en
Short-container-title:Orphanet J Rare Dis

Author:

Gutierrez Laura,Patris Julien,Hutchings Adam,Cowell Warren

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Genetics (clinical),General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13023-015-0269-y.pdf

Reference74 articles.

1. Euoropean Commission. Pharmaceutical comittee 17 March 2015. http://ec.europa.eu/health/files/committee/74meeting/pharm684.pdf. Accessed 10 April 2015.

2. European Commission. Regulation (EC) No 141/2000 of the European parliament and of the council of 16 December 1999 on orphan medicinal products. http://ec.europa.eu/health/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf. Accessed 13 Feb 2015

3. Aymé S, Rodwell C, eds. 2013 report on the state of the art of rare disease activities in Europe. 2013. http://www.eucerd.eu/upload/file/Reports/2013ReportStateofArtRDActivities.pdf. Accessed 13 Feb 2015.

4. European Commission. Policy, Rare diseases – what are they? http://ec.europa.eu/health/rare_diseases/policy/index_en.htm. Accessed 13 Feb 2015.

5. Simoens S, Picavet E, Dooms M, Cassiman D, Morel T. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11(1):1–3.

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining ‘therapeutic value’ of medicines: a scoping review;BMJ Open;2023-12

2. Literature Review on Health Emigration in Rare Diseases—A Machine Learning Perspective;International Journal of Environmental Research and Public Health;2023-01-30

3. The actual status of drug prices and adjustment factors for drug price calculation: an analysis of ultra-orphan drug development in Japan;Orphanet Journal of Rare Diseases;2022-11-08

4. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations;Social Science & Medicine;2022-08

5. Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?;Orphanet Journal of Rare Diseases;2022-04-05